Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.
Analyst Ratings Changes
A number of research analysts have commented on TDOC shares. Craig Hallum decreased their price target on Teladoc Health from $67.00 to $30.00 in a research note on Thursday, April 28th. Canaccord Genuity Group lowered their target price on Teladoc Health from $50.00 to $45.00 in a report on Thursday, July 28th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Teladoc Health from $44.00 to $34.00 in a research note on Friday, July 29th. Bank of America raised their price objective on shares of Teladoc Health from $36.00 to $42.00 and gave the company a "neutral" rating in a research note on Wednesday, July 6th. Finally, Oppenheimer cut their target price on shares of Teladoc Health from $65.00 to $55.00 and set an "outperform" rating on the stock in a research note on Thursday, July 28th. Two equities research analysts have rated the stock with a sell rating, twenty-two have assigned a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $67.90.
Teladoc Health Stock Performance
Shares of NYSE:TDOC traded down $0.86 during midday trading on Thursday, reaching $35.09. 117,810 shares of the company were exchanged, compared to its average volume of 6,220,573. Teladoc Health has a 1 year low of $27.38 and a 1 year high of $156.82. The stock has a fifty day simple moving average of $37.04 and a 200 day simple moving average of $49.98. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.38.
Insiders Place Their Bets
In other news, CFO Mala Murthy sold 4,053 shares of the business's stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $37.32, for a total value of $151,257.96. Following the transaction, the chief financial officer now owns 27,295 shares of the company's stock, valued at $1,018,649.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, SVP Daniel Trencher sold 1,000 shares of the firm's stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $41.12, for a total value of $41,120.00. Following the completion of the sale, the senior vice president now owns 27,408 shares in the company, valued at $1,127,016.96. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Mala Murthy sold 4,053 shares of Teladoc Health stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $37.32, for a total value of $151,257.96. Following the completion of the sale, the chief financial officer now directly owns 27,295 shares in the company, valued at approximately $1,018,649.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,053 shares of company stock valued at $221,498. 1.55% of the stock is owned by company insiders.